Follow-up Study on Chronic Myeloid Leukemia Patients Achieving Treatment-free Remission

National Taiwan University logo

National Taiwan University




Chronic Myeloid Leukemia, BCR/ABL-Positive

Study type


Funder types




Details and patient eligibility


In recent years, the goal of stopping drug therapy, also known as treatment-free remission (TFR), is emerging as one of the management goals of chronic myeloid leukemia (CML) therapy. Because there is no available data on Asian patients with CML undergoing tyrosine kinase inhibitor discontinuation (TKI), the investigators plan to recruit chronic phase CML patients with deep treatment response and good medical compliance in Taiwan to evaluate the feasibility, safety and clinical consequences of TKI discontinuation.

Full description

1. Primary goal: To evaluate the feasibility, safety and clinical consequences of TKI discontinuation in chronic phase CML(CP-CML) patients with deep treatment response and good medical compliance in Taiwan 2. Molecular response monitoring: After discontinuation of TKI therapy, participants will receive monthly molecular monitoring of BCR-ABL transcript levels by real-time quantitative polymerase chain reaction (RT-qPCR) for one year, every two months for the second year and every three months thereafter. If loss of major molecular response (MMR) (BCR-ABL transcript level ⩽ 0.1% IS) is detected at any time point post TKI discontinuation, the participant should receive repeated testing within two weeks. If loss of MMR is confirmed, TKI should be resumed within four weeks RT-qPCR of BCR-ABL would be ordered every four weeks until MR4 (BCR-ABL transcript level ⩽ 0.01% IS) is re-established, and then every 12 weeks indefinitely. For patients who fails to achieve MMR again within three months after TKI is re-initiated, BCR-ABL kinase domain mutation testing would be performed


100 estimated patients




20+ years old


No Healthy Volunteers

Inclusion criteria

1. The participant should be an adult (age ⩾20 years) with CP-CML. 2. The BCR-ABL fusion should be in the form of either e13a2 or e14a2 (p210) 3. The participant should not have documented resistance to a 2nd-generation TKI (Nilotinib or Dasatinib) 4. The participant should have received ≥ 5 years of consecutive treatment with imatinib, or ≥ 4 years of consecutive treatment with a 2nd-generation TKI (Nilotinib or Dasatinib) 5. The participant should have achieved MR4.5 (BCR-ABL ⩽0.0032% IS) or undetectable disease in the peripheral blood or bone marrow, for ≥ 2 years, which is documented on ≥ 4 separate tests performed ≥ 3 months apart. 6. Access to a reliable qPCR-based BCR-ABL test with a sensitivity of detecting of at least MR4.5.

Exclusion criteria

1. After evaluation, the participant is deemed to be ineligible by the investigator of this study. 2. The participant has no intention to be recruited into this study.

Trial contacts and locations



Central trial contact

Wen-Chien Chou, MD. PhD.

Data sourced from

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems